摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-benzyl-6-bromoquinazolin-4-amine | 307538-35-8

中文名称
——
中文别名
——
英文名称
N-benzyl-6-bromoquinazolin-4-amine
英文别名
——
N-benzyl-6-bromoquinazolin-4-amine化学式
CAS
307538-35-8
化学式
C15H12BrN3
mdl
——
分子量
314.184
InChiKey
CRIVWOZDTPNCTP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    458.8±35.0 °C(Predicted)
  • 密度:
    1.522±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    4
  • 重原子数:
    19
  • 可旋转键数:
    3
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.07
  • 拓扑面积:
    37.8
  • 氢给体数:
    1
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    描述:
    N-benzyl-6-bromoquinazolin-4-amine吡啶potassium carbonate 作用下, 以 乙醇 为溶剂, 反应 1.08h, 生成 N-(5-(4-(benzylamino)quinazolin-6-yl)pyridin-3-yl)methanesulfonamide
    参考文献:
    名称:
    [EN] COMBINATION WITH CHECKPOINT INHIBITORS TO TREAT CANCER
    [FR] COMBINAISON D'INHIBITEURS DE POINTS DE CONTRÔLE POUR LE TRAITEMENT DU CANCER
    摘要:
    一种组合物包括化合物的公式(I)和/或公式(Ia),或其药用可接受的盐,以及至少一种免疫检查点调节剂。预防和治疗癌症的方法包括向需要的受试者施用该组合物的治疗有效量,该组合物包括:化合物的公式(I)和/或公式(Ia),或其药用可接受的盐,以及至少一种免疫检查点调节剂。
    公开号:
    WO2020215037A1
  • 作为产物:
    描述:
    6-溴-4-氯喹唑啉苄胺 以62%的产率得到N-benzyl-6-bromoquinazolin-4-amine
    参考文献:
    名称:
    [EN] COMBINATION WITH CHECKPOINT INHIBITORS TO TREAT CANCER
    [FR] COMBINAISON D'INHIBITEURS DE POINTS DE CONTRÔLE POUR LE TRAITEMENT DU CANCER
    摘要:
    一种组合物包括化合物的公式(I)和/或公式(Ia),或其药用可接受的盐,以及至少一种免疫检查点调节剂。预防和治疗癌症的方法包括向需要的受试者施用该组合物的治疗有效量,该组合物包括:化合物的公式(I)和/或公式(Ia),或其药用可接受的盐,以及至少一种免疫检查点调节剂。
    公开号:
    WO2020215037A1
点击查看最新优质反应信息

文献信息

  • Small molecule inhibitors of EGFR and PI3K
    申请人:The Regents of the University of Michigan
    公开号:US10206924B2
    公开(公告)日:2019-02-19
    This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a quinazoline structure or a quinoline structure which function as dual inhibitors of EGFR proteins and PI3K proteins, and their use as therapeutics for the treatment of cancer and other diseases.
    本发明属于药物化学领域。特别是,本发明涉及一类具有喹唑啉结构或喹啉结构的新型小分子,它们可作为表皮生长因子受体蛋白和 PI3K 蛋白的双重抑制剂,并可用作治疗癌症和其他疾病的疗法。
  • [EN] SMALL MOLECULE INHIBITORS OF EGFR AND PI3K<br/>[FR] INHIBITEURS À PETITE MOLÉCULE DE L'EGFR ET DE PI3K
    申请人:UNIV MICHIGAN REGENTS
    公开号:WO2016100347A3
    公开(公告)日:2016-08-18
  • Fabrication of Furan-Functionalized Quinazoline Hybrids: Their Antibacterial Evaluation, Quantitative Proteomics, and Induced Phytopathogen Morphological Variation Studies
    作者:Qing-Su Long、Li-Wei Liu、Yong-Liang Zhao、Pei-Yi Wang、Biao Chen、Zhong Li、Song Yang
    DOI:10.1021/acs.jafc.9b03419
    日期:2019.10.9
    The limited number of agrochemicals targeting plant bacterial diseases has driven us to develop highly efficient, low-cost, and versatile antibacterial alternatives. Herein, a novel type of simple furan-functionalized quinazolin-4-amines was systematically fabricated and screened for their antibacterial activity. Bioassay results revealed that compounds C-1 and E-4 could substantially block the growth of two frequently mentioned pathogens Xanthomonas oryzae pv oryzae and X. axonopodis pv citri in vitro, displaying appreciable EC50 values of 7.13 and 10.3 mg/L, respectively. This effect was prominently improved by comparing those of mainly used agrochemicals. An in vivo experiment against bacterial blight further illustrated their viable applications as antimicrobial ingredients. Quantitative proteomics demonstrated that C-1 possessed a remarkable ability to manipulate the upregulation and downregulation of expressed proteins, which probably involved D-glucose and biotin metabolic pathways. This finding was substantially verified by parallel reaction monitoring analysis. Scanning electron microscopy images and fluorescence spectra also indicated that the designed compounds had versatile capacities for destroying the integrity of bacteria. Given these remarkable characteristics, furan-functionalized quinazoline hybrids can serve as a viable platform for developing innovative antibiotic alternatives against bacterial infections.
  • SMALL MOLECULE INHIBITORS OF EGFR AND PI3K
    申请人:The Regents of The University of Michigan
    公开号:EP3233085A2
    公开(公告)日:2017-10-25
  • COMBINATION WITH CHECKPOINT INHIBITORS TO TREAT CANCER
    申请人:The Regents Of The University Of Michigan
    公开号:EP3955923A1
    公开(公告)日:2022-02-23
查看更多